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Background: Literature is still arguing about a possible relationship between airway hyperresponsiveness (AHR) and
body mass index (BMI). This study aimed at evaluating the influence of BMI on AHR and pulmonary function in
children and adolescents that performed a methacholine test for suggestive asthma symptoms.
Methods: 799 consecutive children/adolescents (535 M; mean age: 15 ± 3 yrs; median FEV1% predicted: 101.94%
[93.46-111.95] and FEV1/FVC predicted: 91.07 [86.17-95.38]), were considered and divided into underweight, normal,
overweight and obese. Different AHR levels were considered as moderate/severe (PD20 ≤ 400 μg) and borderline
(PD20 > 400 μg).
Results: 536 children/adolescents resulted hyperreactive with a median PD20 of 366 μg [IQR:168–1010.5]; 317
patients were affected by moderate/severe AHR, whereas 219 showed borderline hyperresponsiveness. Obese
subjects aged > 13 years showed a lower (p = 0.026) median PD20 (187μg [IQR:110–519]) compared to overweight
(377 μg [IQR:204–774]) and normal-weight individuals’ values (370.5 μg [IQR:189–877]). On the contrary, median
PD20 observed in obese children aged ≤ 13 years (761 μg [IQR:731–1212]) was higher (p = 0.052) compared to
normal-weight children’s PD20 (193 μg [IQR:81–542]) and to obese adolescents’ values (aged > 13 years)
(p = 0.019). Obesity was a significant AHR risk factor (OR:2.853[1.037-7.855]; p = 0.042) in moderate/severe AHR
adolescents. Females showed a higher AHR risk (OR:1.696[1.046-2.751] p = 0.032) compared to males. A significant
relationship was found between BMI and functional parameters (FEV1, FVC, FEV1/FVC) only in hyperreactive females.
Conclusions: Obesity seems to influence AHR negatively in female but not in male adolescents and children. In fact,
AHR is higher in obese teenagers, in particular in those with moderate/severe hyperresponsiveness, and may be mediated
by obesity-associated changes in baseline lung function.
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Many researches have shown that asthma and obesity are
associated. In particular, the increase in body mass index
(BMI) has been associated with an increased incidence and
prevalence of asthma in pediatric population [1-4]. How-
ever, available clinical data on obesity and airway hyper-
responsiveness (AHR), which is a feature of asthma, are
conflicting. In fact, many studies, concerning this topic and
conducted on children, have not demonstrated any rela-
tionships between BMI and airway hyperresponsiveness* Correspondence: bsposat@tin.it
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reproduction in any medium, provided the or[5-9]. Other studies, on the contrary, have shown that a
higher BMI was associated with a higher AHR [10-12].
These conflicting results may be due to the fact that, in a
few studies, a diagnosis of asthma is sometimes established
on symptoms reported by children’s parents. Furthermore,
this may also be due to over-diagnosis of asthma because
obesity-related chest symptoms may in fact mimic asthma.
In addition, when a higher cut-off value is used to define
a positive bronchial provocation test, asthma diagnosis
may be overestimated [13] and this can obviously influ-
ence the outcome of the BMI relationship. Also, a regular
use of inhaled corticosteroids, bronchodilators and anti-
leukotriens may change the results in bronchial provoca-
tion tests [14,15].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with regard to gender. In fact, some authors found that a
higher BMI was related to a higher PC20 (a lower airway
reactivity) in female children but not in males [6]. On the
contrary, Huang et al. noted a decreased prevalence of
AHR in the lowest quintile of BMI in teenage girls [10].
Another study observed that BMI was associated with
AHR in school-age boys [11].
There are also controversial data on a possible influence
of BMI on pulmonary function; some authors found a re-
duction in FEV1, FVC and FEV1/FVC with a weight in-
crease [6,16,17], whereas the opposite was observed by
other authors [18]. Besides, studies often associate children
with adolescents, without taking into account that puberty
can influence asthma differently [19]. Also smoking can
have a negative impact on bronchial hyperreactivity [20].
Therefore, taking all this into account, the aim of our
retrospective study was to assess whether there is a rela-
tionship between BMI and AHR, especially in different
levels of AHR, in children and adolescents that had
undergone a methacholine challenge test for suspected
asthma. We also tried to assess whether smoking could
interfere with the correlation between BMI and AHR.
Another aim was to evaluate whether there is an associ-
ation between BMI and baseline lung function. In order
to limit the influence of treatment, only subjects who
were not treated regularly with asthma medications were
included in the study.
Methods
Subjects
In our retrospective study, we analyzed the results of
821 consecutive methacholine challenge tests on subjects
aged < 18 years performed between 2000 and 2008 in the
Pneumology Unit, “Misericordia” Hospital, Grosseto and
in the Pneumology and UTIP Unit, “S. Donato” Hospital,
Arezzo, Tuscany, Italy.
All subjects reported symptoms suggestive of asthma
(unexplained episodes of cough and/or wheezing and/or
dyspnea on exertion) associated with a normal baseline
lung function and they all had performed the methacholine
test in order to confirm the diagnosis of asthma. Only 799
consecutive subjects (535 M; mean age 15 ± 3yrs; median
FEV1% 101.94 [93.46-111.95] and FEV1/FVC 91.07 [86.17-
95.38]), were suitable for the study. Twenty-two subjects
were excluded because they had not completed the test as
showing a fall in FEV1> 10% with buffer solution, thus
there were no PD20 values in these subjects. FEV1, FEV1/
FVC, FVC, FEF25-75, measured at baseline (pre-Mch test)
and PD20FEV1 recorded in each bronchoprovocation test
were considered for the study. Smoking habits, age, sex
and BMI were also taken into account.
None of the subjects was under regular asthma treatment
when the test was performed. Subjects who had takendrugs when required were asked to avoid taking any medi-
cations prior to the test: β2-agonist bronchodilators and in-
haled or systemic corticosteroids were suspended 24 hours
and 3 weeks before the test respectively, while antihista-
mines were suspended at least 10 days before the challenge.
No subjects had suffered from airway infections or asthma
exacerbations in the four weeks prior to the test. Inter-
national age and sex specific cut off points for BMI were
used to subdivide subjects with age < 18 years into under-
weight, normal or overweight-obese [21,22]. BMI was cal-
culated by dividing the weight in kilograms by the square of
height in metres (kg/m2). Cut-offs used to divide the cases
in the various weight classes, were equivalent to adult BMI
values. Children/adolescents that showed an adult corre-
sponding value less than 18.5 or between 18.5 and 25 or
between 25 and 30 or > 30 were considered as under-
weight, normal weight, overweight and obese, respectively.
The use of data for the purpose of the study was ap-
proved by the local Ethic Committees which did not re-
tain necessary to obtain any informed consent from each
patient because data were retrospectively and anonym-
ously analyzed.
Mch bronchoprovocation test
The Mch bronchoprovocation test was performed by
using a dosimeter method [13]. The same instrument
and method were used both in Grosseto and Arezzo.
Mch sulphate was supplied by Lofarma (Milan, Italy)
and administered in aerosol form using a MEFAR MB3
dosimeter (output: 9 μL/puff; MEFAR Elettromedicali
Brescia, Italy) with MB2 ampoule model. The buffer solu-
tion was the first to be administered, followed by 40 μg of
methacholine, increasing the doses until PD20FEV1 was
obtained or until the maximum dose of Mch was reached.
FEV1 was assessed after inhaling 40, 80, 120, 240, 400,
800, 1,600, and 2,400 μg of cumulative Mch doses, re-
spectively. At the end of exhalation, during tidal breathing,
patients inhaled Mch slowly and deeply for 5 seconds and
then held their breath for 5 seconds more. The test was
interrupted if a drop in FEV1> 10% took place with the
buffer solution. The interval between two consecutive
steps was 2 minutes. FEV1 was measured at 30 and 90 sec-
onds after nebulization. A suitable quality of FEV1 was
obtained at each step. No more than two maneuvers after
each dose were allowed, and the highest FEV1 value was
considered. AHR was defined by a 20% fall of FEV1 value
from the reference one (see below) obtained with a cumu-
lative Mch dose < 2,400 μg. Subjects who did not achieve
a 20% fall in FEV1 with a Mch dose of 2,400 μg were
regarded as normoreactive.
Subjects with PD20 ≤ 400 and PD20 > 400 μg were con-
sidered as affected by moderate to severe and borderline
AHR respectively, with the aim of evaluating the effects of
BMI on the different levels of AHR.
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HP 47120E Pulmonary System Desk spirometer (Hewlett
Packard, Waltham, Massachusetts - USA). FEV1 and FVC
were expressed as percentages of the predicted values at
baseline, whereas FEV1/FVC was reported only as a ratio
(reference equation: CECA, 1971). PD20 FEV1 was assessed
by linear interpolation of the dose–response curves. The
FEV1 measured before administering the buffer solution
was taken as baseline value, while the FEV1 measured after
the buffer solution was used as reference value to calculate
FEV1 fall and thus PD20.Statistical analysis
Categorical variables are expressed as number of cases
and percentages. Continuous variables are expressed as
mean values and standard deviations or median values and
interquartile range (IQR – 25° and 75° quartiles) according
to whether they are normally distributed. Nonparametric or
parametric tests were performed accordingly. Comparisons
of qualitative data were performed using the chi-square
test, whereas comparisons of quantitative variables among
underweight, overweight, normal weight and obese subjects
were conducted by either the ANOVA one-way test or
Kruskall-Wallis test. Moreover, the Bonferroni test was
used for multiple comparisons. Assessments of any possi-
ble differences between the different categories considered
(males vs females, smoking vs non-smoking and children vs
adolescents) were assessed with the Kruskal Wallis and
Mann Whitney tests. Associations between BMI and PD20,
in different categories and classes of subjects considered,
were analyzed using Spearman correlation test.
Five logistic binary regression models, corrected for
sex, age, smoking, FEV1, FVC and seasons, were applied
separately in overall subjects and then in males, females,
children and adolescents to evaluate if BMI was an inde-
pendent AHR risk factor. In order to assess a potential
different risk of BMI on AHR in the various levels of
hyperresponsiveness (moderate to severe and borderline
AHR), comparing it to subjects with normal reactivity, two
additional logistic regression models were performed for
each group considered. In these models, BMI was consid-
ered as qualitative variables (underweight, normal weight,
overweight and obese).
Five linear regression models (corrected for age, sex,
smoking habits and seasons) were also performed separ-
ately in overall subjects and then in males, females, children
and adolescents, with the purpose of assessing a possible
relationship between BMI and pulmonary function (FEV1,
FVC, FEV1/FVC). β-coefficients were also calculated separ-
ately for each group in subjects with moderate/severe and
borderline AHR. P < 0.05 was considered statistically sig-
nificant. The statistical package SPSS (16.0) was used for
analysis.Results
A different distribution of patients with dissimilar weight
was found both in males and in females. The age was lower
in underweight subjects. Also, FEV1, FVC and FEV1/FVC
were lower in these subjects compared to normal-weight,
overweight and obese patients (Table 1).
No meaningful relationships (Spearman’s correlation)
between PD20 and BMI were found when the subjects
were considered as a whole and also when subdivided
into subjects with moderate/severe and borderline AHR.
No relationships were found either in males, females,
smokers, non-smokers, normal weight/underweight, obese
subjects, children (aged< 13) or adolescents (aged> 13) even
when they were divided into moderate/severe and border-
line AHR individuals. Only in overweight subjects, when
considered as a whole, a significant relationship was found
between PD20 and BMI (r= −0.267; p < 0.039) (data not
shown).
No differences were found in PD20 values in under-
weight, overweight, normal weight and obese males and
females, even when compared each other (Figure 1a). Also,
when considered separately, in subjects with moderate/
severe and borderline AHR (Figure 1c), median PD20 values
were the same in each weight group. On the contrary, non-
smoking obese subjects showed a lower (p = 0.024) median
PD20 value (183.5 μg [IQR:84–519]) in comparison with
non-smokers and overweight children/adolescents (443 μg
[IQR:256–846]) (Figure 1b). When we considered the dif-
ferent age classes (Figure 1d), a lower (p = 0.026) median
PD20 value was measured (187 μg [IQR:110–519]) in obese
subjects aged > 13 years compared to overweight (377 μg
[IQR:204–774]) and normal-weight (370.5 μg [IQR:189–
877]) individuals. On the contrary, the median PD20 value
measured in obese children aged ≤ 13 years (761 μg [IQR:
731–1212]) was higher (p=0.052) than that observed in
normal-weight children (193 μg [IQR:81–542]). Further-
more, this latter PD20 value, measured in obese children
(aged ≤ 13years), was different even from that observed in
obese adolescents (aged > 13 years) (p = 0.019) (Figure 1d).
No differences were observed in AHR prevalence either
in the different groups of subjects (underweight, over-
weight, normal-weight and obese) or in the various sub-
groups (males, females, different-age groups, smokers and
non-smokers) (Figure 2).
The logistic regression model (Table 2)showed that in
all hyperreactive subjects the obese condition (in com-
parison to subjects with normal weight) resulted to be a
risk factor (corrected for age, sex, smoking habits, FEV1,
FVC and seasons) for AHR (OR: 2.653 [1.055-6.673], p =
0.038; Table 2). When subjects were analyzed for differ-
ent AHR degrees, the obesity condition was a risk factor
for AHR only in subjects that showed a moderate/severe
AHR (OR: 2.874 [1.059-7.800], p=0.038) but not in bor-
derline AHR individuals (2.299 [0.809-6.528], p=0.118).
Table 1 Baseline characteristics of 799 patients
Underweight Normal weight Overweight Obese All p
All subjects n. (%) 144 (18.02) 526 (65.83) 90 (12.39) 40 (5) 799 (100) < 0.001
Males n. (%) 78 (14.57) 360 (67.29) 70 (13.08) 26 (4.85) 535 (100) 0.001
Females n. (%) 66 (25.98) 165 (64.96) 20 (7.87) 13 (5.11) 264 (100)
Age (mean ± SD) 12 ± 4*° # 15 ± 3* 16 ± 2° 16 ± 2# 15 ± 3 < 0.001
Children, age (mean ± SD) 9.9 ± 2.3 11.1 ± 2* 11.8 ± 1.4* 10.7 ± 1.5 10.8 ± 1.9 0.0001
Adolescents, age (mean ± SD) 16.1 ± 1.3 16.5 ± 1.4 16.7 ± 1.4 16.6 ± 1.3 16.4 ± 1.4 0.126
Smokers n. (%) 7 (7.7%) 68 (16.2%) 17 (22.1%) 4 (12.9%) 96 (15.5%) 0.069
Subjects with normal
reactivity n. (%)
47 (32.6%) 179 (33.7%) 31 (34.4%) 6 (17.6%) 263 (32.9%) 0.279
Hyperreactive subjects
(PD20 < 2400 μg) n. (%)
97 (67.4%) 352 (66.3%) 59 (65.6%) 28 (82.4%) 536 (67.1%)
FEV1% 99.31 [88.58-108.15]*°
# 102.53 [94.28-111.87]* 104.47 [94.48-114.61]° 105.41 [95.48-113.14]# 101.94 [93.46-111.95] 0.005
FVC % 90.1 [82.64-98.29]*° # 96.67 [88.22-105.12]* 99.24 [90.97-109.74]° 99.71 [90.21-109.50]# 95.89 [87.46-104.28] < 0.001
FEV1/FVC 93.90 [8.51-97.56]*°
# 90.88 [86.47-95.04]* 89.15 [84.16-93.96]° 89.23 [85.73-93.44]# 91.07 [86.17-95.38] < 0.001
BMI 17.15 [16.28-17.91] 21.36 [19.97-22.83] 26.51 [25.65-27.76] 32.45 [31.25-35.57] 21.23 [19.15-23.61] < 0.001
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; BMI, body mass index. The continuous variables are median (interquartile range [IQR]) or mean ± standard deviation and categorical values are
expressed as number of cases (percentage). Mean comparisons were made with the ANOVA test; median comparisons were made with the Kruskal-Wallis test; proportion comparisons were made with the χ2 test; post
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Figure 1 PD20values measured in underweight, normal weight, overweight and obese males, females (a), smokers, non-smokers (b),
moderate to severe and borderline AHR (c), and in those aged≤13 and>13 years(d). Comparisons were made with Kruskal Wallis and Mann
Whitney tests. §p = 0.024: obese non-smokers in comparison with overweight non-smokers; °p = 0.026: obese subjects aged > 13 years compared
to overweight and normal weight adolescents (aged > 13 years); *p = 0.052: obese children (aged ≤ 13 years) compared to children aged ≤ 13
years with normal weight; #p = 0.019: obese children (aged ≤ 13 years) compared to obese adolescents (aged > 13 years). §p = 0.01.
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in all AHR levels (data not reported). At this stage, we
applied separate logistic regression models considering
only males, females, children (aged ≤ 13 years) and adoles-
cents (aged > 13 years) (Table 2). In females, even if not
statistically significant, a higher odd ratio value in obese
women was noted, especially in those with moderate/
severe AHR (OR:4.380 [0.417-46.009]) showing that the
risk of AHR might be higher in obese females. On the
contrary, the obese condition resulted a significant risk
factor for AHR (OR:2.853 [1.037-7.855]; p = 0.042) in ado-
lescents (aged > 13 years) with moderate/severe AHR.
When this logistic regression model was applied, we also
noted that females’ conditions were a significant risk
factor for AHR (OR:1.696 [1.046-2.751]; p = 0.032) in
adolescents with moderate/severe hyperresponsiveness.
This was not observed either in all subjects, when consid-
ered as a whole, or in those aged ≤ 13 years (data notshown). Furthermore, FEV1 resulted to be a significant pro-
tective factor from AHR whereas FVC was a risk factor in
all regression logistic models applied (data not shown).
In the attempt to find possible explanations for the
above-described associations between BMI and AHR, we
applied the regression linear models in order to connect
lung function and BMI, adjusted for age, season, smok-
ing habits and sex, when possible (Table 3). No rela-
tionships between BMI and pulmonary function were
observed either in males or in the different age classes.
We only noted a significant variation of FEV1 and FVC
for a BMI unit increase in females with AHR but not in
those with normal bronchial reactivity (see Table 3 for
values in bold).
Discussion
This research highlights that obesity can influence airway
hyperresponsiveness especially in asthmatic adolescents
Figure 2 Prevalence of subjects with airway hyperresponsiveness (PD20 < 2,400 μg) obtained in underweight, normal weight,
overweight and obese males, females (a), smokers, non-smokers (b), moderate/severe and borderline AHR (c), and in those aged ≤ 13
and>13 years(d). No differences among different groups and sub-groups (χ2 tests).
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challenge test but not in children whose weight increase,
on the contrary, might have a positive effect on bronchial
hyperresponsiveness. Furthermore, obesity is a significant
risk factor for AHR in females rather than in male adoles-
cents and children. Our data show that this effect may be
mediated in females by an influence of BMI on pulmonary
function.
As already said, an important and original finding of
this study is the different influence of BMI in different
age classes, especially in children and adolescents. In
the first class, no significant negative effects of BMI
were observed. On the contrary, weight increase seems
to be related to a higher PD20 value. In fact, a higher
PD20 was observed in obese children, in comparison to
those with normal weight and even with obese adoles-
cents. Some authors observed that a higher BMI was
not a risk factor for airway hyperresponsiveness in ei-
ther boys or girls aged ≤ 12 years [7,8], whereas others,
like us, found that BMI was even positively associated
with PC20 in children aged 7–12 years and with increas-
ing spirometric values [6]. This suggested a possible
protective effect of weight in children. The discovery ofa positive association between PC20 and BMI was still
somewhat puzzling. No explanation has been found in
literature. This positive relationship between BMI and
AHR may be simply due to the fact that several obese
children, rather than those with normal weight, may be
not asthmatics because in reality obesity-related chest
symptoms may be mistaken for asthma [5]. On the con-
trary, a lower PD20 value was measured in obese adoles-
cents aged > 13 years when compared to overweight and
normal weight individuals. Also other studies showed that
BMI was a significant AHR predictor in adolescents
[10,16]. These results may be justified by the fact that the
effects of obesity on AHR may occur only after a certain
period of time from its onset. In fact, children who had a
persistent high BMI during childhood, had a significantly
increased risk of having AHR when they were 8 years old,
whereas those that normalized their BMI from 6 to 7 years,
did not have an increased AHR risk at the age of 8 [12].
Therefore, the possible negative effects induced by pro-
inflammatory molecules (leptin, tumor necrosis factor α
(TNF-α), interleukin 6 (IL-6), transforming growth factor
β1 (TGF-β1), C-reactive protein, adiponectin and resistin)
on AHR and in general on asthma [23,24], may be delayed
Table 2 OR obtained in all subjects with AHR (PD20 < 2400 μg) and in those with only moderate/severe (PD20 ≤ 400 μg) or borderline AHR (PD20 > 400 μg) in
comparison to subjects with normal reactivity
All AHR subjects (PD20 < 2400 μg) Subjects with moderate/severe AHR (PD20 < 400 μg) Subjects with borderline AHR (PD20>400 μg)
OR 95% CI p OR 95% CI p OR 95% CI p
All underweight subjects 0.814 0.522-1.268 0.362 0.800 0.478-1.338 0.396 0.815 0.463-1.434 0.478
All overweight subjects 0.976 0.598-1.594 0.955 0.876 0.490-1.566 0.654 0.958 0.534-1.721 0.887
All obese subjects 2.653 1.055-6.673 0.038 2.874 1.059-7.800 0.038 2.299 0.809-6.528 0.118
Underweight males 0.609 0.336-1.104 0.102 0.525 0.265-1.041 0.065 0.559 0.261-1.199 0.135
Overweight males 1.011 0.577-1.772 0.969 0.809 0.413-1.586 0.537 0.992 0.515-1.911 0.980
Obese males 2.404 0.864-6.691 0.093 2.480 0.804-7.649 0.114 2.208 0.697-6.995 0.178
Underweight females 1.221 0.607-2.456 0.576 1.487 0.645-3.429 0.352 1.399 0.573-3.417 0.461
Overweight females 0.766 0.272-2.159 0.614 1.250 0.383-4.079 0.711 0.572 0.138-2.372 0.441
Obese females 4.058 0.439-37.557 0.217 4.380 0.417-46.009 0.118 2.863 0.210-39.048 0.430
Underweight subjects (age≤13yrs) 0.788 0.396-1.566 0.496 0.616 0.276-1.374 0.236 1.078 0.442-2.629 0.869
Overweight subjects(age≤13yrs) 1.244 0.326-4.749 0.749 1.250 0.219-7.142 0.802 3.066 0.568-16.551 0.193
Obese subjects (age≤13yrs) 1.952 0.177-21.516 0.585 1.565 0.069-35.417 0.778 3.934 0.313-49.423 0.289
Underweight subjects (age>13) 0.828 0.447-1.537 0.550 0.986 0.474-2.052 0.970 0.744 0.335-1.652 0.468
Overweight subjects(age>13) 0.935 0.547-1.597 0.805 0.851 0.455-1.593 0.615 0.802 0.423-1.522 0.500
Obese subjects (age>13) 2.390 0.933-6.125 0.070 2.853 1.037-7.855 0.042 1.580 0.510-4.891 0.428
Five different logistic regression models (respectively for overall, males, females, children and adolescents) were applied and corrected for sex (where appropriate), age, smoking habits, FEV1, FVC and seasons. Odd




















Table 3 Relationship between lung function (measured at baseline, before the Mch test) and BMI (linear regression









β p β p β p β p
FVC% (All) 0,161 0,123 0,167 0,293 0,239 0,217 0,227 0,353
FEV1% (All) −0,077 0,410 −0,105 0,473 −0,168 0,326 −0,087 0,690
FEV1/FVC (All) 0,099 0,383 0,131 0,463 0,132 0,523 0,187 0,469
FVC% (Males) 0.053 0.730 0.086 0.611 0.107 0.748 0.158 0.615
FEV1% (Males) 0.010 0.942 −0.007 0.962 −0.056 0.851 −0.033 0.905
FEV1/FVC (Males) 0.001 0.994 0.035 0.855 0.046 0.895 0.126 0.707
FVC% (Females) 0.411 0.027 0.934 0.035 0.390 0.015 0.240 0.471
FEV1% (Females) −0.348 0.036 −0.849 0.036 −0.315 0.024 −0.095 0.744
FEV1/FVC (Females) 0.290 0.147 0.882 0.059 0.075 0.665 0.195 0.575
FVC% (Age ≤13) −0,060 0,725 −0,038 0,803 0,094 0,927 −0,177 0,713
FEV1% (Age ≤13) 0,112 0,469 0,099 0,485 −0,054 0,953 0,225 0,611
FEV1/FVC (Age ≤13) −0,189 0,314 −0,127 0,470 −0,223 0,825 −0,173 0,720
FVC% (Age>13) 0,174 0,261 0,260 0,327 0,124 0,525 0,144 0,561
FEV1% (Age>13) −0,119 0,399 −0,193 0,438 −0,084 0,633 −0,023 0,916
FEV1/FVC (Age>13) 0,108 0,523 0,228 0,444 0,015 0,944 0,070 0,790
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effects.
Another reason for this difference between children
and adolescents may be due to pubertal sex hormone
differences. In particular, this difference should regard
females because they have a precocious puberty in com-
parison with males. In fact, as already said, we found a
lower PD20 in obese adolescents if compared to obese
children. Furthermore, an enhanced AHR risk was found in
adolescents with moderate/severe AHR. The risk evaluation
in the two sexes showed that it was 38% greater in females
when compared to males. This means that obesity influ-
ences only female adolescents and not male adolescents or
children, which is perfectly in line with what was assessed
in another study of ours [20] and in previous researches
[23,25,26] where a higher AHR risk was observed only in
adult females. Female adolescents become adults more pre-
cociously than males. Therefore, BMI influences AHR only
when it interacts with some features that are acquired dur-
ing adulthood. Sex hormone differences may play an im-
portant role in this dissimilar behaviour. In particular
estrogens may play a role in modulating the relationship
between BMI and asthma. In fact, the estrogens level in-
creases with obesity favouring an early menarche in women
and a delay in the onset of puberty in men [23]. It was
found that the prevalence of asthma and the association be-
tween BMI with the severity of the disease were greater in
women with an early menarche [27,28]. Furthermore, it
seems that estrogens and progesterone may modify the
inflammatory response to favour a Th2 response [23].β-estradiol enhances eosinophil adhesion to human
mucosal micro-vascular endothelial cells and may induce
degranulation (unlike the testosterone effect), whereas pro-
gesterone increases bronchial eosinophilia and enhances
bronchial responsiveness [29,30]. In addition, this different
hormonal pattern determines a greater subcutaneous fat
distribution, while in males it causes a higher visceral adi-
pose tissue localization. Subcutaneous abdominal fat ap-
pears to increase the risk of airway hyperreactivity, while
visceral abdominal fat seems not to be associated with AHR
[31]. In particular, a higher level of bronchial hyperre-
sponsiveness (after a hypertonic saline challenge test) was
associated with a gynoid fat mass in females [32]. Subcuta-
neous fat, rather than visceral fat, produces a higher
amount of leptin (with greater values in females compared
to males) which may be responsible for asthma worsening
in obese women [23,33,34]. In fact, leptin may induce air-
way inflammation in asthmatics. A relationship between
circulating leptin levels and risk of asthma development
was observed in females [34]. Recently, an increased neu-
trophilic inflammation was found only in asthmatic obese
females [25]. Another research observed that a gynoid fat
mass is associated with a lower concentration of airway
eosinophils in females [25]. Therefore, BMI may influence
AHR differently in males and females with a dissimilar in-
flammatory pattern induced by obesity. Likely, a higher
production of leptin from subcutaneous adipose tissue,
which is typical of females, promotes T-helper type 1 cell
differentiation and increases activation of neutrophils via
tumour necrosis factor α [35].
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http://www.mrmjournal.com/content/8/1/60An alternative explanation for our findings could be ei-
ther the purely mechanical effect of weight on pulmonary
function, and consequently on AHR, or an indirect effect of
systemic inflammation (as already pointed out) on bron-
chial reactivity via a lung function impairment. In fact, we
observed a FEV1 reduction and an increase in FVC for unit
of increase in BMI in female adolescents who already
showed an association between BMI and AHR. Further-
more, we also found that an increase in FEV1 and FVC
resulted to be significantly protective and risk factors for
AHR respectively in all classes of subjects considered. This
means that a BMI increase determines functional alter-
ations consistent with an obstructive pattern in female ado-
lescents. This is in accordance with a previous study of
ours, carried out on adults, where we found a significant re-
duction of FEV1/FVC ratio only in females with moderate
AHR [20]. Also other researchers found a FEV1/FVC re-
duction both in obese children [6] and adults [36], though
this was not confirmed by other authors [32,37]. This more
significant BMI-induced obstruction could consequently in-
fluence AHR. In our study, FEV1 increase was an AHR pro-
tective factor, thus suggesting that a reduction of lung
function may lead to AHR. An excess soft tissue weight
compressing the thoracic cage, a fatty infiltration of chest
wall and an increase in pulmonary blood volume, could
contribute to determine a reduction in lung volumes for
a mechanical effect especially in females [26,36,38]. This
is associated with an impairment in the lung inflation-
induced airway distensibility and a reduction in peripheral
airway diameter, which, over time, may perturb smooth
muscle function thus increasing both airway obstruction
and AHR [23]. BMI seems not to influence lung function
in males while it appears to have a significant impact in fe-
males. It is likely that the smaller airway calibre in females
may be influenced by BMI-induced obstruction in a more
pronounced way than in males. This is supported by other
studies which also observed a greater effect of adipose tis-
sue on females’ lung function compared to males [25,39].
In children, as already said, no relationships between BMI
and lung function was found. However, other researchers
reported contradictory results. Some authors found reduced
values of FEV1, FVC and FEV1/FVC in healthy [17] and
asthmatics overweight and obese children [6,16] while
others reported spirometric measurement increases in par-
allel with body weight and BMI [6,18]. These conflicting re-
sults may be due to an influence of growth variability in
children. A possible negative effect of obesity on lung func-
tion may be hidden by a positive effect due to growth.
Another interesting result was the dissimilar influence
of BMI on the two AHR different levels considered. The
logistic regression models showed a diverse relationship
between BMI and the different levels of AHR (moder-
ate/severe and borderline). A significant risk for AHR
was only found in subjects with moderate/severehyperresponsiveness and not in those with borderline
reactivity. The absence of any association between BMI
and AHR in borderline hyperresponsiveness is certainly
due to the fact that a great proportion of subjects be-
longing to this group ended up by not being asthmatics.
In fact, high values of PD20 or PC20, in case of suspected
asthma (like in our patients), make an asthma diagnosis
less probable [13]. Bronchial hyperresponsiveness is a
characteristic of asthma and inflammation is related to
AHR. In fact, some researchers found that nitric oxide
levels significantly increase with the increasing ofbronchial
hyperresponsiveness in asthmatics [40,41]. Therefore, it
seems that obesity interacts only with subjects affected by
asthma and especially with those suffering from a more se-
vere form. Obesity is considered as an inflammatory status,
because proinflammatory molecules, expressed by adipose
tissue such as leptin, TNF-α, IL-6, TGF- β1, adiponectin
and C-reactive protein, are increased in obese subjects
[23,25], especially in females (mainly C-reactive protein
and leptin) [20]. Thus, obesity, with additional inflamma-
tion, may have a variable role, like several other environ-
mental events (i.e. allergens, respiratory infections, and
treatment), in increasing the pre-existing bronchial
hyperreactivity [13]. In confirmation of this, weight loss,
through bariatric surgery, produces significant improve-
ments in exhaled nitric oxide in obese asthmatic patients
and in AHR, especially in those with normal serum IgE
levels [42,43].
Conclusions
Obesity seems to be a risk factor for a greater airway
hyperresponsiveness in female adolescents rather than in
males and above all in children. Furthermore, this risk ap-
pears to involve only subjects with moderate/severe hyper-
responsiveness and not those with borderline AHR. The
relationship between BMI and AHR may be mediated by
obesity-associated changes in baseline lung function.
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